RSS

Alnylam Pharmaceuticals

The US Food and Drug Administration (FDA) has approved the first RNA-based therapy for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Read more

News

RNAi therapeutics company, Alnylam Pharmaceuticals, has revealed that the CHMP has adopted a positive opinion on the use of patisiran for the treatment of hereditary transthyretin-mediated amyloidosis in adults with stage 1 or 2 polyneuropathy Read more

News

Sanofi and RNAi therapeutics company, Alnylam Pharmaceuticals, have begun strategic restructuring of their RNAi therapeutics alliance to streamline and optimise development and commercialisation of certain products Read more

News